The Complexity of a dengue vaccine: A review of the human antibody response

PLoS Neglected Tropical Diseases

Volumn 9, Issue 6, 2015, Pages 1-18

  Flipse, Jacky ^a   Smit, Jolanda M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; E ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PRM ANTIBODY; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENGUE; DENGUE VIRUS 2; DRUG EFFICACY; FLAVIVIRUS INFECTION; HUMAN; IMMUNOREACTIVITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEROCONVERSION; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; ANTIBODY DEPENDENT ENHANCEMENT; BIOSYNTHESIS; DENGUE VIRUS; IMMUNOLOGY; PHYSIOLOGY; STANDARDS; T LYMPHOCYTE;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; DENGUE VACCINES; DENGUE VIRUS; EPITOPES; HUMANS; T-LYMPHOCYTES;

EID: 84934758127     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003749     Document Type: Review

References (113)

1. Sips GJ, Wilschut J, Smit JM. Neuroinvasive flavivirus infections. Rev Med Virol. 2012; 22: 69-87. doi: 10. 1002/rmv. 712 PMID: 22086854
2. European Centre for Disease Prevention and Control. Annual epidemiological report 2012. guidelines for the surveillance of invasive mosquitoes in Europe. stockholm: ECDC; 2012
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013; 496: 504-507. doi: 10. 1038/nature12060 PMID: 23563266
4. Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res. 1999; 53: 35-70. PMID: 10582094
5. World Health Organization. Fact sheet: Dengue and severe dengue. Http://www. who. int/mediacentre/ factsheets/fs117/en/index. html. 2012;March 2013: 1.
6. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012; 30: 4301-4306. doi: 10. 1016/j. vaccine. 2011. 09. 114 PMID: 22682286
7. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010; 84: 10630- 10643. doi: 10. 1128/JVI. 01190-10 PMID: 20702644
8. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010; 6: e1000821. doi: 10. 1371/journal. ppat. 1000821 PMID: 20333252
9. Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from europe and asia. J Gen Virol. 1999; 80 (Pt 1): 179-185.
10. Sotelo E, Fernandez-Pinero J, Llorente F, Vazquez A, Moreno A, Aguero M, et al. Phylogenetic relationships of western mediterranean west nile virus strains (1996-2010) using full-length genome sequences: Single or multiple introductions? J Gen Virol. 2011; 92: 2512-2522. doi: 10. 1099/vir. 0. 033829-0 PMID: 21775579
11. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in bangkok. Am J Trop Med Hyg. 1988; 38: 172-180. PMID: 3341519
12. Mizumoto K, Ejima K, Yamamoto T, Nishiura H. On the risk of severe dengue during secondary infection: A systematic review coupled with mathematical modeling. J Vector Borne Dis. 2014; 51: 153-164. PMID: 25253207
13. Halstead SB. Immune enhancement of viral infection. Prog Allergy. 1982; 31: 301-364. PMID: 6292921
14. Russell PK, Yuill TM, Nisalak A, Udomsakdi S, Gould DJ, Winter PE. An insular outbreak of dengue hemorrhagic fever. II. virologic and serologic studies. Am J Trop Med Hyg. 1968; 17: 600-608. PMID: 4970512
15. Buchy P, Vo VL, Bui KT, Trinh TX, Glaziou P, Le TT, et al. Secondary dengue virus type 4 infections in vietnam. Southeast Asian J Trop Med Public Health. 2005; 36: 178-185. PMID: 15906664
16. Halstead SB. Dengue. The Lancet. 2007; 370: 1644-1652.
17. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011; 29: 587-619. doi: 10. 1146/annurev-immunol-031210-101315 PMID: 21219187
18. Wan SW, Lin CF, Wang S, Chen YH, Yeh TM, Liu HS, et al. Current progress in dengue vaccines. J Biomed Sci. 2013; 20: 37-0127-20-37.
19. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: Preclinical, industrial and clinical development of the sanofi pasteur tetravalent dengue vaccine. Vaccine. 2011; 29: 7229-7241. doi: 10. 1016/j. vaccine. 2011. 06. 094 PMID: 21745521
20. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in mexico. Hum Vaccin Immunother. 2014; 10: 2853-2863. doi: 10. 4161/21645515. 2014. 972131 PMID: 25483647
21. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008; 26: 5712-5721. doi: 10. 1016/j. vaccine. 2008. 08. 019 PMID: 18762226
22. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013; 110: E2046-53. doi: 10. 1073/pnas. 1305227110 PMID: 23580623
23. Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis. 2011; 203: 103-108. doi: 10. 1093/infdis/jiq022 PMID: 21148502
24. da Costa VG, Marques-Silva AC, Floriano VG, Moreli ML. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials. Vaccine. 2014; 32: 4885-4892. doi: 10. 1016/j. vaccine. 2014. 07. 008 PMID: 25045816
25. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in thai schoolchildren: A randomised, controlled phase 2b trial. Lancet. 2012; 380: 1559-1567. doi: 10. 1016/ S0140-6736(12)61428-7 PMID: 22975340
26. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, Boaz M, Starr-Spires L, Thakur M, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: A randomized, controlled, phase II trial in latin america. Pediatr Infect Dis J. 2013; 32: 1102-1109. doi: 10. 1097/INF. 0b013e31829b8022 PMID: 24067553
27. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384: 1358-1365. doi: 10. 1016/ S0140-6736(14)61060-6 PMID: 25018116
28. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in latin america. N Engl J Med. 2015; 372(1): 113-123.
29. Wilder-Smith A. Dengue vaccines: Dawning at last? Lancet. 2014; 384: 1327-1329. doi: 10. 1016/ S0140-6736(14)61142-9 PMID: 25018119
30. Sabin AB. The dengue group of viruses and its family relationships. Bacteriol Rev. 1950; 14: 225-232. PMID: 14772197
31. Snow GE, Haaland B, Ooi EE, Gubler DJ. Review article: Research on dengue during world war II revisited. Am J Trop Med Hyg. 2014; 91: 1203-1217. doi: 10. 4269/ajtmh. 14-0132 PMID: 25311700
32. Yamanaka A, Tabuchi Y, Mulyatno KC, Susilowati H, Hendrianto E, Soegijanto S, et al. Dengue virus infection-enhancing and neutralizing antibody balance in children of the philippines and indonesia. Microbes Infect. 2012; 14: 1152-1159. doi: 10. 1016/j. micinf. 2012. 07. 013 PMID: 22841680
33. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in thailand. J Infect Dis. 2014; 209: 360-368. doi: 10. 1093/infdis/jit436 PMID: 23964110
34. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013; 7: e2357. doi: 10. 1371/journal. pntd. 0002357 PMID: 23951377
35. Sharp TM, Hunsperger E, Munoz-Jordan JL, Margolis HS, Tomashek KM. Sequential episodes of dengue-puerto rico, 2005-2010. Am J Trop Med Hyg. 2014.
36. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9: 921-927. PMID: 12808447
37. Midgley CM, Bajwa-Joseph M, Vasanawathana S, LimpitikulW, Wills B, Flanagan A, et al. An indepth analysis of original antigenic sin in dengue virus infection. J Virol. 2011; 85: 410-421. doi: 10. 1128/JVI. 01826-10 PMID: 20980526
38. Gwinn W, Sun W, Innis BL, Caudill J, King AD. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg. 2003; 69: 39-47. PMID: 14740954
39. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1. 2a. J Clin Invest. 1996; 98: 1684-1691. PMID: 8833919
40. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015; 89: 120-128. doi: 10. 1128/JVI. 02129-14 PMID: 25320311
41. Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in singapore. Hum Vaccin Immunother. 2013; 9: 2317-2325. PMID: 23839107
42. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis. 2012; 6: e1568. doi: 10. 1371/journal. pntd. 0001568 PMID: 22448292
43. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis. 2011; 204: 1514-1522. doi: 10. 1093/infdis/jir607 PMID: 21930609
44. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014; 10: e1004386. doi: 10. 1371/journal. ppat. 1004386 PMID: 25275316
45. Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, et al. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol. 2013; 87: 12562-12575. doi: 10. 1128/JVI. 00871-13 PMID: 24027331
46. Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in nicaraguan dengue cases. PLoS Negl Trop Dis. 2013; 7: e2451. doi: 10. 1371/journal. pntd. 0002451 PMID: 24069496
47. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988; 38: 411-419. PMID: 3354774
48. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. infection enhancement by non-neutralizing antibody. J Exp Med. 1977; 146: 201-217. PMID: 406347
49. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000; 181: 2-9. PMID: 10608744
50. Moi ML, Takasaki T, Saijo M, Kurane I. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg. 2013; 107: 51-58. doi: 10. 1093/trstmh/trs007 PMID: 23296697
51. Flipse J, Wilschut J, Smit JM. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic. 2013; 14: 25-35. doi: 10. 1111/tra. 12012 PMID: 22998156
52. Rothman AL. Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011; 11: 532-543. doi: 10. 1038/nri3014 PMID: 21760609
53. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis. 2010; 10: 712-722. doi: 10. 1016/S1473-3099(10)70166-3 PMID: 20883967
54. Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol. 1999; 73: 6104-6110. PMID: 10364366
55. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. Arch Virol. 1997; 142: 897-916. PMID: 9191856
56. Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk W, et al. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 2007; 3: e183. PMID: 18052531
57. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010; 8: 271-283. doi: 10. 1016/j. chom. 2010. 08. 007 PMID: 20833378
58. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol. 2012; 86: 2665-2675. doi: 10. 1128/JVI. 06335-11 PMID: 22171265
59. Setthapramote C, Sasaki T, Puiprom O, Limkittikul K, Pitaksajjakul P, Pipattanaboon C, et al. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophys Res Commun. 2012; 423: 867-872. doi: 10. 1016/j. bbrc. 2012. 06. 057 PMID: 22713454
60. Heinz FX, Mandl C, Berger R, Tuma W, Kunz C. Antibody-induced conformational changes result in enhanced avidity of antibodies to different antigenic sites on the tick-borne encephalitis virus glycoprotein. Virology. 1984; 133: 25-34. PMID: 6199892
61. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg. 1985; 34: 162-169. PMID: 2578750
62. Monath TP, Wands JR, Hill LJ, Gentry MK, Gubler DJ. Multisite monoclonal immunoassay for dengue viruses: Detection of viraemic human sera and interference by heterologous antibody. J Gen Virol. 1986; 67 (Pt 4): 639-650.
63. Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine. 2003; 21: 3675-3683. PMID: 12922097
64. Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg. 2003; 68: 469-476. PMID: 12875299
65. Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol. 1988; 69 (Pt 8): 2101-2107. PMID: 3404125
66. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis. 2013; 207: 1898-1908. doi: 10. 1093/infdis/jit119 PMID: 23526830
67. DejnirattisaiW, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, LimpitikulW, et al. Crossreacting antibodies enhance dengue virus infection in humans. Science. 2010; 328: 745-748. doi: 10. 1126/science. 1185181 PMID: 20448183
68. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011; 5: e1188. doi: 10. 1371/journal. pntd. 0001188 PMID: 21713020
69. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012; 109: 7439-7444. doi: 10. 1073/pnas. 1200566109 PMID: 22499787
70. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: A veiled pathogen? PLoS Pathog. 2010; 6: e1000718. doi: 10. 1371/journal. ppat. 1000718 PMID: 20062797
71. Rodenhuis-Zybert IA, da Silva Voorham JM, Torres S, van de Pol D, Smit JM. Antibodies against immature virions are not a discriminating factor for dengue disease severity. PLoS Negl Trop Dis. 2015; 9: e0003564. doi: 10. 1371/journal. pntd. 0003564 PMID: 25760350
72. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in thailand. J Infect Dis. 2004; 189: 990-1000. PMID: 14999601
73. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008; 82: 6631- 6643. doi: 10. 1128/JVI. 00316-08 PMID: 18448542
74. Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009; 4: e4991. doi: 10. 1371/journal. pone. 0004991 PMID: 19337372
75. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells. J Virol. 2001; 75: 7769-7773. PMID: 11462053
76. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007; 81: 12816-12826. PMID: 17881453
77. Moreland NJ, Susanto P, Lim E, Tay MY, Rajamanonmani R, Hanson BJ, et al. Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci. 2012; 13: 2618-2635. doi: 10. 3390/ijms13032618 PMID: 22489114
78. Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauss J, Aberle JH, et al. Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol. 2014; 88: 13845-13857. doi: 10. 1128/JVI. 02086-14 PMID: 25253341
79. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, et al. Induction of epitope-specific neutralizing antibodies against west nile virus. J Virol. 2007; 81: 11828-11839. PMID: 17715236
80. Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 2013; 9: e1003458. doi: 10. 1371/ journal. ppat. 1003458 PMID: 23818856
81. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology. 2009; 392: 103-113. doi: 10. 1016/j. virol. 2009. 06. 037 PMID: 19631955
82. Wahala WM, Huang C, Butrapet S, White LJ, de Silva AM. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol. 2012; 86: 4019-4023. doi: 10. 1128/JVI. 06871-11 PMID: 22278250
83. DejnirattisaiW, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015; 16: 170-177. doi: 10. 1038/ni. 3058 PMID: 25501631
84. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012; 4: 139ra83.
85. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A. 2014; 111: 1939-1944. doi: 10. 1073/pnas. 1317350111 PMID: 24385585
86. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol. 2014; 88: 12233-12241. doi: 10. 1128/JVI. 00247-14 PMID: 25100837
87. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol. 2014; 5: 93. doi: 10. 3389/fimmu. 2014. 00093 PMID: 24639680
88. Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in vero cells (VDV3). Vaccine. 2006; 24: 4914-4926. PMID: 16632108
89. Mongkolsapaya J, Duangchinda T, DejnirattisaiW, Vasanawathana S, Avirutnan P, Jairungsri A, et al. T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? J Immunol. 2006; 176: 3821-3829. PMID: 16517753
90. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005; 175: 2676-2683. PMID: 16081844
91. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol. 2004; 78: 2701-2710. PMID: 14990690
92. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 2013; 9: e1003723. doi: 10. 1371/journal. ppat. 1003723 PMID: 24204271
93. World Health Organization. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07 07. 2007.
94. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17: 1055- 1065. doi: 10. 1128/CVI. 00131-10 PMID: 20463105
95. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009; 81: 825-833. doi: 10. 4269/ajtmh. 2009. 08-0625 PMID: 19861618
96. Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J. Variation in dengue virus plaque reduction neutralization testing: Systematic review and pooled analysis. BMC Infect Dis. 2012; 12: 233-2334-12-233.
97. Salje H, Rodriguez-Barraquer I, Rainwater-Lovett K, Nisalak A, Thaisomboonsuk B, Thomas SJ, et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis. 2014; 8: e2952. doi: 10. 1371/ journal. pntd. 0002952 PMID: 24967885
98. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of west nile virus. PLoS Pathog. 2011; 7: e1002111. doi: 10. 1371/journal. ppat. 1002111 PMID: 21738473
99. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013; 4: e00873-13. doi: 10. 1128/mBio. 00873-13 PMID: 24255124
100. Mahalingam S, Herring BL, Halstead SB. Call to action for dengue vaccine failure. Emerg Infect Dis. 2013; 19: 1335-1337. doi: 10. 3201/eid1908. 121864 PMID: 23876389
101. Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis. 2014; 8: e3230. doi: 10. 1371/journal. pntd. 0003230 PMID: 25329173
102. Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, et al. Cross-protective capacity of japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis. 2013; 56: 267-270. doi: 10. 1093/cid/cis883 PMID: 23074319
103. Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S. Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in ratchaburi cohort, thailand. Virol J. 2014; 11: 48-422X-11-48.
104. Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in malaysia: A randomized, placebocontrolled, phase III study. Vaccine. 2013; 31: 5814-5821. doi: 10. 1016/j. vaccine. 2013. 10. 013 PMID: 24135573
105. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody- mediated neutralization of flavivirus infection: Implications for vaccine development. Cell Host Microbe. 2008; 4: 229-238. doi: 10. 1016/j. chom. 2008. 08. 004 PMID: 18779049
106. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a sri lankan pediatric cohort. J Infect Dis. 2014.
107. Rabaa MA, Klungthong C, Yoon IK, Holmes EC, Chinnawirotpisan P, Thaisomboonsuk B, et al. Frequent in-migration and highly focal transmission of dengue viruses among children in kamphaeng phet, thailand. PLoS Negl Trop Dis. 2013; 7: e1990. doi: 10. 1371/journal. pntd. 0001990 PMID: 23350000
108. Caron M, Grard G, Paupy C, Mombo IM, Bikie Bi Nso B, Kassa Kassa FR, et al. First evidence of simultaneous circulation of three different dengue virus serotypes in africa. PLoS One. 2013; 8: e78030. doi: 10. 1371/journal. pone. 0078030 PMID: 24205075
109. Halstead SB. Dengue vaccine development: A 75% solution? Lancet. 2012; 380: 1535-1536. doi: 10. 1016/S0140-6736(12)61510-4 PMID: 22975339
110. Li XQ, Qiu LW, Chen Y, Wen K, Cai JP, Chen J, et al. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: Implications for dengue vaccine design. J Gen Virol. 2013; 94: 2191-2201. doi: 10. 1099/vir. 0. 055178-0 PMID: 23851440
111. Sessions OM, Tan Y, Goh KC, Liu Y, Tan P, Rozen S, et al. Host cell transcriptome profile during wildtype and attenuated dengue virus infection. PLoS Negl Trop Dis. 2013; 7: e2107. doi: 10. 1371/ journal. pntd. 0002107 PMID: 23516652
112. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine. 1994; 12: 503-507. PMID: 8036823
113. Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, et al. Circulation of type 1 vaccine- derived poliovirus in the philippines in 2001. J Virol. 2004; 78: 13512-13521. PMID: 15564462